Coughing, sneezing, and high temperature are common signs of a cold. While these may look harmless, they can also be symptoms ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) -- which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

Infants are among the most susceptible to respiratory complications from respiratory syncytial virus, or RSV. While they can ...

It’s called respiratory syncytial virus (RSV), and even if you’ve never heard of it before, there’s a very good chance that you’ve had it in the past. The virus is a common cause of ...

The highly contagious respiratory syncytial virus (RSV) typically causes mild illness, but it can lead to severe respiratory complications, particularly for at-risk individuals. Drawing on local ...

For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associat ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...

as the presentation is indistinguishable from other respiratory tract infections, and epidemics often overlap. The microbiologic confirmation of RSV infection is based on detecting the virus in a ...